Intra-aortic balloon counterpulsation - Does it work?


Journal

Progress in cardiovascular diseases
ISSN: 1873-1740
Titre abrégé: Prog Cardiovasc Dis
Pays: United States
ID NLM: 0376442

Informations de publication

Date de publication:
Historique:
received: 01 07 2020
accepted: 01 07 2020
pubmed: 9 7 2020
medline: 22 12 2020
entrez: 9 7 2020
Statut: ppublish

Résumé

The intra-aortic balloon pump (IABP) has been in routine use for various cardiovascular indications for 5 decades. However, its regular use has been increasingly questioned. The aim of IABP counterpulsation is to enhance coronary blood flow and to reduce afterload of the left ventricle. In-vivo studies, however, provided insight into how physiological responses might counteract the desired effects of the device. Large randomized trials did not show benefit of IABP in the main indications such as infarct-related cardiogenic shock, high-risk myocardial infarction without shock and elective high-risk percutaneous coronary intervention. As these results are reflected differently in international guidelines and the interpretation of the evidence is heterogeneous, the frequency of IABP use differs considerably by region. Current research efforts predominantly focus on other active mechanical circulatory support devices making evidence-based approaches for possible final IABP niches more difficult.

Identifiants

pubmed: 32640282
pii: S0033-0620(20)30138-9
doi: 10.1016/j.pcad.2020.07.001
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

623-629

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Auteurs

Anne Freund (A)

Heart Center Leipzig at University of Leipzig and Leipzig Heart Institute, Leipzig, Germany; German Center for Cardiovascular Research (DZHK), Berlin, Germany. Electronic address: anne.freund@medizin.uni-leipzig.de.

Steffen Desch (S)

Heart Center Leipzig at University of Leipzig and Leipzig Heart Institute, Leipzig, Germany; German Center for Cardiovascular Research (DZHK), Berlin, Germany.

Holger Thiele (H)

Heart Center Leipzig at University of Leipzig and Leipzig Heart Institute, Leipzig, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH